The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting the company's ambition to transition into an AI-driven global healthcare platform, Greg Siokas, CEO of Cosmos Health, issued a shareholder letter highlighting robust financial performance. According to reports, the company achieved record revenue during FY2025 and the first quarter of 2026, underscoring the success of its accelerated growth strategy. Furthermore, the company established an ambitious roadmap targeting revenue exceeding $200 million by 2029, with a primary focus on expanding its footprint in the U.S. market.
These results arrive as the AI-driven healthcare sector experiences significant momentum, with market data estimating the global market size at approximately $31.67 billion in 2025 (per Grand View Research). For Cosmos Health, FY2025 revenue reached $65.3 million, a 20% year-over-year increase, while Q1 2026 revenue surged 31% to $17.9 million (per Investing.com data). This positive top-line growth contrasts with ongoing profitability challenges, as the company reported a net loss of $2.81 million for the first quarter of 2026.
Sign in to access this content
Sign InInvestors should monitor COSM stock levels, which closed at 0.208 EUR on the Tradegate exchange as of June 10, 2026, amid high volatility that has seen the share price decline nearly 55% year-to-date. Operationally, markets will look toward the annual shareholder meeting scheduled for July 15, 2026 (per the economic calendar), which is expected to address equity incentive plans and the issuance of Series B Preferred Stock to fund future expansion.